Skip to main content
Premium Trial:

Request an Annual Quote

Michael Kranda, Paul Allen

Premium

Michael Kranda has joined Vulcan, the investment company for the assets of Microsoft co-founder Paul Allen, to direct life sciences investment. Prior to joining Vulcan, Kranda was CEO of Oxford Glycosciences, which was acquired by UK biotech firm Celltech in June. Prior to that, he was president, COO, and director at Immunex.

Filed under

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.